Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC) (ADAPT)

Share this content:
Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC) (ADAPT)

Sponsors and Collaborators
Argos Therapeutics

Contact
Jill Yarbrough
919-287-6309
jyarbrough@argostherapeutics.com

Principal Investigators
Robert Figlin, MD, FACP, Cedars-Sinai Medical Center
Christopher G Wood, MD, FACP, M.D. Anderson Cancer Center

ClinicalTrials.gov Identifier
NCT01582672

You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters